Skip to main content
. 2009 Oct 13;9:54. doi: 10.1186/1471-2377-9-54

Figure 2.

Figure 2

Prevalence of NAbs according to the clinical response. Within the groups of patients showing poor clinical response (Group A and B), only 16 out of 94 patients (17.0%) are NAb-positive and 78 (83%) are NAb-negative. This suggests that NAbs presence explains only partially the poor clinical response to IFNβ.